NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
Sellas Life Sciences Group
Beth Israel Deaconess Medical Center
Marker Therapeutics, Inc.
San Antonio Military Medical Center
San Antonio Military Medical Center
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
M.D. Anderson Cancer Center